Literature DB >> 31303426

Systemic Lupus Erythematosus and Increased Prevalence of Atherosclerotic Cardiovascular Disease in Hospitalized Patients.

Gregory Katz1, Nathaniel R Smilowitz1, Ashira Blazer2, Robert Clancy2, Jill P Buyon2, Jeffrey S Berger3.   

Abstract

OBJECTIVE: To assess the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its individual phenotypes of coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease by age and sex in a large US cohort of hospitalized patients with systemic lupus erythematosus (SLE).
METHODS: A nested case-control study of adults with and without SLE was conducted from the January 1, 2008, through December 31, 2014, National Inpatient Sample. Hospitalized patients with SLE were matched (1:3) by age, sex, race, and calendar year to hospitalized patients without SLE. The prevalences of CAD, PAD, and cerebrovascular disease were evaluated, and associations with SLE were determined after adjustment for common cardiovascular risk factors.
RESULTS: Among the 252,676 patients with SLE and 758,034 matched patients without SLE, the mean age was 51 years, 89% were women, and 49% were white. Patients with SLE had a higher prevalence of ASCVD vs those without SLE (25.6% vs 19.2%; OR, 1.45; 95% CI, 1.44-1.47; P<.001). After multivariable adjustment, SLE was associated with a greater odds of ASCVD (adjusted odds ratio [aOR], 1.46; 95% CI, 1.41-1.51). The association between SLE and ASCVD was observed in women and men and was attenuated with increasing age. Also, SLE was associated with increased odds of CAD (aOR, 1.42; 95% CI, 1.40-1.44), PAD (aOR, 1.25; 95% CI, 1.22-1.28), and cerebrovascular disease (aOR, 1.68; 95% CI, 1.65-1.71).
CONCLUSION: In hospitalized US patients, SLE was associated with increased ASCVD prevalence, which was observed in both sexes and was greatest in younger patients.
Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31303426      PMCID: PMC6711365          DOI: 10.1016/j.mayocp.2019.01.044

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  28 in total

Review 1.  Systemic lupus erythematosus.

Authors:  George C Tsokos
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

2.  Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study.

Authors:  C Bengtsson; M-L Ohman; O Nived; S Rantapää Dahlqvist
Journal:  Lupus       Date:  2011-11-07       Impact factor: 2.911

3.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal
Journal:  Arthritis Rheum       Date:  2001-10

4.  National trends in pediatric systemic lupus erythematosus hospitalization in the United States: 2000-2009.

Authors:  Andrea M Knight; Pamela F Weiss; Knashawn H Morales; Ron Keren
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

5.  Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus.

Authors:  M M Ward
Journal:  Arthritis Rheum       Date:  1999-02

6.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  Mary J Roman; Beth-Ann Shanker; Adrienne Davis; Michael D Lockshin; Lisa Sammaritano; Ronit Simantov; Mary K Crow; Joseph E Schwartz; Stephen A Paget; Richard B Devereux; Jane E Salmon
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

7.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

Authors:  Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

8.  Lipoprotein(a) levels in systemic lupus erythematosus.

Authors:  E F Borba; R D Santos; E Bonfa; C G Vinagre; F J Pileggi; W Cossermelli; R C Maranhão
Journal:  J Rheumatol       Date:  1994-02       Impact factor: 4.666

Review 9.  Understanding the epidemiology and progression of systemic lupus erythematosus.

Authors:  Guillermo J Pons-Estel; Graciela S Alarcón; Lacie Scofield; Leslie Reinlib; Glinda S Cooper
Journal:  Semin Arthritis Rheum       Date:  2009-01-10       Impact factor: 5.532

10.  The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program.

Authors:  Peter M Izmirly; Isabella Wan; Sara Sahl; Jill P Buyon; H Michael Belmont; Jane E Salmon; Anca Askanase; Joan M Bathon; Laura Geraldino-Pardilla; Yousaf Ali; Ellen M Ginzler; Chaim Putterman; Caroline Gordon; Charles G Helmick; Hilary Parton
Journal:  Arthritis Rheumatol       Date:  2017-09-10       Impact factor: 10.995

View more
  9 in total

1.  T cells expressing the lupus susceptibility allele Pbx1d enhance autoimmunity and atherosclerosis in dyslipidemic mice.

Authors:  Wei Li; Ahmed S Elshikha; Caleb Cornaby; Xiangyu Teng; Georges Abboud; Josephine Brown; Xueyang Zou; Leilani Zeumer-Spataro; Brian Robusto; Seung-Chul Choi; Kristianna Fredenburg; Amy Major; Laurence Morel
Journal:  JCI Insight       Date:  2020-06-04

2.  Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease.

Authors:  Risa Wakiya; Kiyo Ueeda; Hiromi Shimada; Shusaku Nakashima; Tomohiro Kameda; Nobuyuki Miyatake; Mikiya Kato; Taichi Miyagi; Koichi Sugihara; Mao Mizusaki; Rina Mino; Norimitsu Kadowaki; Hiroaki Dobashi
Journal:  Clin Rheumatol       Date:  2022-07-18       Impact factor: 3.650

Review 3.  Prevention of Coronary Artery Disease in Women.

Authors:  Ellen Liu; Allison Bigeh; Lauren Ledingham; Laxmi Mehta
Journal:  Curr Cardiol Rep       Date:  2022-06-14       Impact factor: 3.955

4.  Systemic Lupus Erythematosus and Cardiovascular Disease: A Mendelian Randomization Study.

Authors:  Ning Gao; Minjian Kong; Xuebiao Li; Dongdong Wei; Xian Zhu; Ze Hong; Ming Ni; Yifan Wang; Aiqiang Dong
Journal:  Front Immunol       Date:  2022-06-06       Impact factor: 8.786

5.  Anti-Müllerian hormone in African-American women with systemic lupus erythematosus.

Authors:  Meghan Angley; Jessica B Spencer; S Sam Lim; Penelope P Howards
Journal:  Lupus Sci Med       Date:  2020-11

6.  Cardiovascular risk assessment in lupus nephritis and ANCA-associated vasculitis in real-world nephrology practice.

Authors:  Hui Zhuan Tan; Irene Y J Mok; Nigel Fong; Zhihua Huang; Jason C J Choo; Cynthia C Lim
Journal:  Clin Kidney J       Date:  2022-03-03

7.  Systemic lupus erythematosus and the risk of cardiovascular diseases: A two-sample Mendelian randomization study.

Authors:  Shuo Huang; Fugang Huang; Chunyun Mei; Fengyuan Tian; Yongsheng Fan; Jie Bao
Journal:  Front Cardiovasc Med       Date:  2022-09-02

Review 8.  A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.

Authors:  Thomas Bieber; Eugen Feist; Alan D Irvine; Masayoshi Harigai; Ewa Haladyj; Susan Ball; Walter Deberdt; Maher Issa; Susanne Grond; Peter C Taylor
Journal:  Adv Ther       Date:  2022-09-05       Impact factor: 4.070

Review 9.  Elucidating the Intriguing Association Between Systemic Lupus Erythematosus and Cardiovascular Disease.

Authors:  Mushrin Malik; Rajvi Gor; Nabeel A Siddiqui; Dhairya Gor; Kazi I Ahmed
Journal:  Cureus       Date:  2021-06-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.